cas 218594-79-7|| where to buy (S)-3-(Hydroxymethyl)morpholine Hydrochloride

Nom du produit:(S)-3-(Hydroxymethyl)morpholine Hydrochloride

IUPAC Name:[(3S)-morpholin-3-yl]methanol hydrochloride

Unité d'emballage	Stock disponible	Prix($)
CM116109-1g	in stock	ƻȁ
CM116109-5g	in stock	ȁƻŴ
CM116109-10g	in stock	ɅƀƱ
CM116109-25g	in stock	ƻƻƻ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Notes supplémentaires

Verification code*

refresh

: N° CAS:218594-79-7; Formule moléculaire:C5H12ClNO2; Point de fusion:-; Code SMILES:OC[C@@H]1NCCOC1.[H]Cl; Densité:

: Numéro de catalogue:CM116109; Poids moléculaire:153.61; Point d'ébullition:; N° Mdl:MFCD12547468; Stockage:Store at 2-8°C.

: Morpholines; Morpholine contains secondary amine groups and has all the typical reactive characteristics of secondary amine groups. It can react with inorganic acids to form salts, and react with organic acids to form salts or amides, which can be subjected to alkylation reaction, and can also be reacted with ethylene oxide, ketone or Willgerodt reaction. Morpholine is a six-membered ring containing oxygen and nitrogen, and its alkalinity is much lower than that of its parent piperidine. The marketed morpholine drugs are mainly distributed in the fields of tumors, cardiovascular and cerebrovascular diseases, respiratory system diseases, digestive system diseases, infectious diseases and mental disorders.; morpholine price; if you are interested in morpholine price, please feel free to contact us. More information of our products will be forwarded to you upon receipt of your specific inquiry.

: Elinzanetant; On January 8, 2024, Bayer announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Elinzanetant successfully met all four primary endpoints and all three key secondary endpoints in both studies. Elinzanetant is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist for the non-hormonal treatment of moderate to severe VMS associated with menopause. Elinzanetant may address moderate to severe VMS by modulating a group of estrogen sensitive neurons in the hypothalamus region of the brain (the KNDy neurons) which, with the decrease of estrogen, become hypertrophic and lead to a hyperactivation of the thermoregulatory pathway, consequently disrupting body heat control mechanisms resulting in VMS. Elinzanetant may also decrease sleep disturbances associated with menopause.